COSCIENS Biopharma Inc. engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Ontario. The firm is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The firm's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
COSCIENS Biopharma Inc lĩnh vực doanh thu lớn nhất là Active Ingredient, với doanh thu 11,633,714 trong báo cáo lợi nhuận gần đây. Về mặt địa lý, United States là thị trường chính cho COSCIENS Biopharma Inc, với doanh thu 9,166,413.
COSCIENS Biopharma Inc 是否盈利?
không có,根据最新的财务报表,COSCIENS Biopharma Inc 的净thua lỗ为 $-15